Imperial College London
Alternate

ProfessorRosemaryBoyton

Faculty of Medicine, Department of Infectious Disease

Professor of Immunology and Respiratory Medicine
 
 
 
//

Contact

 

r.boyton

 
 
//

Location

 

8N22Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Alexander:2022,
author = {Alexander, J and Powell, N and Liu, Z and Constable, L and Ibraheim, H and Anandabaskaran, S and Saifuddin, M and Castro, Seoane R and Balarajah, S and Hicks, L and Williams, H and Teare, J and Altmann, D and Boyton, R and Hart, A},
journal = {The Lancet Gastroenterology & Hepatology},
title = {A prospective, case-control study of COVID-19 vaccine-induced antibody responses in immunosuppressed patients with IBD},
url = {http://hdl.handle.net/10044/1/93677},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:We sought to determine whether COVID-19 vaccine-induced antibody responses were diminished in patients with IBD on commonly used immunosuppressive drugs.Methods:We prospectively recruited 483 adults (121 healthy controls and 362 IBD) following two doses of either ChAdOx1 nCoV-19 (Oxford/AstraZeneca), BNT162b2 (Pfizer/BioNTech) or mRNA1273 (Moderna) vaccines (doses delivered between six to twelve weeks apart according to scheduling adopted in the United Kingdom). IBD medications studied comprised thiopurines (n=78), infliximab (n=63), thiopurine/infliximab combination therapy (n=72), ustekinumab (n=57), vedolizumab (n=62) or tofacitinib (n=30). The pre-defined primary outcome was anti-SARS-CoV-2 spike (anti-S1 RBD) antibody concentrations, 53-92 days after second vaccine dose, in 370 participants without prior infection, adjusted by age and vaccine type. Findings:Geometric mean [geometric SD] anti-S1 RBD antibody concentrations were significantly lower in patients treated with infliximab (157U/mL [5.7]; P<0.0001), infliximab and thiopurine combination (111U/mL [5.7]; P<0.0001) and tofacitinib (430 U/mL [3.1]; P=0.0012) compared to controls (1578U/ml [3.7]). There were no significant differences in anti-S1 RBD antibody concentrations between control subjects and thiopurine (1020U/mL [4.3]; P=0.74), nor ustekinumab (582U/mL [4.6]; P=0.11), nor vedolizumab treated patients (954U/mL [4.1]; P=0.50). In multivariable modelling, lower anti-S1 RBD antibody concentrations were independently associated with infliximab (Geometric mean ratio 0.12, 95% CI 0.08-0.17, P<0.0001) and tofacitinib (0.43, 95% CI 0.23-0.81, P=0.009), but not with ustekinumab (0.69, 95% CI 0.41-1.19, P=0.18), thiopurine (0.89, 95% CI [0.64-1.24], P=0.50) or vedolizumab (1.16, 95% CI 0.74-1.83, P=0.51). mRNA vaccines (3.68 [95% CI 2.80-4.84], P<0.0001) and older age (0.79 [95% CI 0.72-0.87], P<0.0001) were independently associated with higher and lower anti-S1 antibody concentrati
AU  - Alexander,J
AU  - Powell,N
AU  - Liu,Z
AU  - Constable,L
AU  - Ibraheim,H
AU  - Anandabaskaran,S
AU  - Saifuddin,M
AU  - Castro,Seoane R
AU  - Balarajah,S
AU  - Hicks,L
AU  - Williams,H
AU  - Teare,J
AU  - Altmann,D
AU  - Boyton,R
AU  - Hart,A
PY  - 2022///
SN  - 2468-1253
TI  - A prospective, case-control study of COVID-19 vaccine-induced antibody responses in immunosuppressed patients with IBD
T2  - The Lancet Gastroenterology & Hepatology
UR  - http://hdl.handle.net/10044/1/93677
ER  -
Download